Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Oncology·MeSH: Recurrence
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| ARV-393 | ARVINAS, INC. (ARVN) |
Frequently asked questions
How many drugs are in development for Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)?
BioSniper tracks 1 drug in development for Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) across 1 company.
How many clinical trials target Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)?
There are 1 clinical trial targeting Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) tracked by BioSniper.
What is the prevalence of Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)?
The estimated prevalence of Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) is approximately 56.0 per 100,000 population.
Deep-dive into Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis